LONDON, Jan 30 (Reuters) - Novo Nordisk said

on Thursday it has not yet posted details about a new trial of

its experimental next-generation obesity drug CagriSema, which

it announced it would start after late-stage trial data in

December disappointed the market.

Reuters reported earlier on Thursday that the Danish

drugmaker will launch a new Phase III trial of the weekly

injection on Feb. 10.

That trial will study the long-term efficacy of CagriSema

and was already planned as part of the REDEFINE series, a

spokesperson said.

(Reporting by Maggie Fick;

Editing by Josephine Mason;)